NEW YORK, Nov. 22, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has donated 3,200 pieces of its hemp-derived CBD functional chewing gum CanChew® to the U.S. Pain Foundation to support the organization’s dedication in empowering caregivers and those who suffer from chronic pain.
The U.S. Pain Foundation is a non-profit organization that educates, connects, informs and empowers those living with chronic pain, while also advocating on behalf of the pain community. While AXIM® Biotech makes no claims that its nutraceutical product CanChew® gum can treat any specific condition, the positive effects of cannabidiol (CBD) for chronic pain sufferers is well established by science today.
“We are honored to support an organization that dedicates itself to helping those with chronic pain, a national epidemic that affects nearly 100 million Americans,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotechnologies. “Like the U.S. Pain Foundation, AXIM also believes in making an impact on individuals’ well-being, which we do through products that treat conditions for which there is currently no effective remedy.”
CanChew® is the world’s first patented controlled-release cannabinoid chewing gum containing 50 mg of hemp oil and 10 mg of cannabidiol (CBD). AXIM® Biotech holds the exclusive rights to market and distribute CanChew® Gum globally. CanChew® is a hemp CBD chewing gum with a unique oral mucosal absorbance delivery system. Features listed on the CanChew® website include:
- Non-habit forming
- No prescription needed
- Available in all 50 states
- Great-tasting mint gum has no artificial sweeteners or preservatives
- Non-GMO, gluten free, vegan and kosher
AXIM’s pipeline of intellectual property (IP) protected cannabinoid-based products include:
- MedChew Rx™ - THC/CBD cannabinoid controlled-release functional chewing gum to address pain and muscle spasticity in multiple sclerosis (MS) patients as well as numerous indication extensions based on the proprietary delivery platform
- RENECANN™ - the world’s first cannabigerol (CBG)-based skincare product line
- ORAXIMAX™ - the world’s first CBG-based oral care product line
- Suppocann™ - a suppository cannabinoid-release product for GI conditions such as IBD, IBS and Crohn’s disease
- Ophthocann™ and Cannbleph™ - cannabinoid-based products for reduction of intraocular pressure and for relief of conjunctivitis
About AXIM ®
AXIM® Biotechnologies, Inc. (OTC:AXIM) is an innovative biotechnology Company focusing on research, development and production of pharmaceutical, nutraceutical and cosmetic products where we prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit the Company website at www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 email@example.com www.cmwmedia.com Corporate Contact Info: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227